SCHEMBL266740

SCHEMBL266740

O=C(Nc1ccc(Cl)cc1C(=O)N/N=C/c1ccc(F)cc1)c1ccncc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.59
MAPT P10636 4/20 0.58
RECQL P46063 1/20 0.58
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
PKM P14618 1/20 0.57
KMT2A Q03164 5/20 0.57
MEN1 O00255 3/20 0.57
POLB P06746 2/20 0.55
CTDSP1 Q9GZU7 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
PSMD14 O00487 1/20 0.55
THRB P10828 1/20 0.55
HPGD P15428 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MITF O75030 1/20 0.54
GPR174 Q9BXC1 1/20 0.54
LMNA P02545 1/20 0.51
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266741 1.00 SMN1; SMN2 (0.59) SMN1; SMN2MAPTRECQLNPC1RAB9A
SCHEMBL266521 0.90 L3MBTL1 (0.65) SMN1; SMN2MAPTRECQLNPC1RAB9A
SCHEMBL266520 0.90 L3MBTL1 (0.65) SMN1; SMN2MAPTRECQLNPC1RAB9A
SCHEMBL267169 0.88 KMT2A (0.57) MAPTNPC1RAB9APKMKMT2A
SCHEMBL267170 0.88 KMT2A (0.57) MAPTNPC1RAB9APKMKMT2A
SCHEMBL268082 0.88 NPC1 (0.60) SMN1; SMN2MAPTNPC1RAB9APKM
SCHEMBL268083 0.88 NPC1 (0.60) SMN1; SMN2MAPTNPC1RAB9APKM
SCHEMBL269059 0.86 NPC1 (0.53) SMN1; SMN2MAPTRECQLNPC1RAB9A
SCHEMBL269060 0.86 NPC1 (0.53) SMN1; SMN2MAPTRECQLNPC1RAB9A
SCHEMBL267334 0.85 RAB9A (0.79) SMN1; SMN2MAPTNPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SMN1; SMN2 3975/4885MAPT 4195/4885RECQL 1619/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SMN1; SMN2 4253/4885MAPT 4648/4885RECQL 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.